Ambrisentan

Generic Name: Ambrisentan

Brand Names: Letairis, Volibris, Ambrisentan Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₂N_₂O_₄

CAS Number: 177036-94-1

Unique Ingredient Identifier: HW6NV07QEC

Background: Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with ...

Indication: 用于治疗肺动脉高血压(PAH)。

Associated Conditions: Pulmonary arterial hypertension WHO functional class I

Associated Therapies: -

Clinical Trials

Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome

Phase 2

Recruiting

Conditions: Acute Kidney Injury
Hepatorenal Syndrome
Liver Cirrhosis
Ascites Hepatic

Interventions: Drug: Terlipressin
Drug: Ambrisentan

First Posted Date: 2024-02-13

Last Posted Date: 2024-06-07

Lead Sponsor: Noorik Biopharmaceuticals AG

Target Recruit Count: 45

Registration Number: NCT06256432

Locations: 🇮🇳
All India Institute of Medical Sciences, New Delhi, Delhi, India
🇮🇳
Aster CMI Hospital, Bangalore, Karnataka, India
🇮🇳
Ganesh Shankar Vidyarthi Memorial (GSVM) Medical College, Kanpur, Uttar Pradesh, India

and more 2 locations

Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation

Phase 2

Not yet recruiting

Conditions: Type 1 Diabetes Mellitus With Diabetic Nephropathy

Interventions: Drug: Sotagliflozin
Drug: Ambrisentan
Drug: Ambrisentan and Sotagliflozin

First Posted Date: 2023-10-10

Last Posted Date: 2023-10-24

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 36

Registration Number: NCT06072326

Locations: 🇨🇦
University of Toronto, Toronto, Canada
🇫🇮
University of Helsinki, Helsinki, Uusimaa, Finland
🇳🇱
Amsterdam University Academic Center, Amsterdam, Noord Holland, Netherlands

and more 4 locations

Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension

Phase 3

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Ambrisentan

First Posted Date: 2022-06-29

Last Posted Date: 2022-06-29

Lead Sponsor: RenJi Hospital

Target Recruit Count: 80

Registration Number: NCT05437224

Locations: 🇨🇳
Renji Hospital, Shanghai, China

Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension

Not Applicable

Recruiting

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Placebo
Drug: Ambrisentan

First Posted Date: 2021-07-22

Last Posted Date: 2022-09-28

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 420

Registration Number: NCT04972656

Locations: 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China

A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19

Phase 2

Terminated

Conditions: Covid19
Hypoxemia

Interventions: Drug: Placebo
Drug: Ambrisentan

First Posted Date: 2021-02-25

Last Posted Date: 2023-03-21

Lead Sponsor: Noorik Biopharmaceuticals AG

Target Recruit Count: 88

Registration Number: NCT04771000

Locations: 🇪🇸
University Hospital 12 de Octubre, Madrid, Spain
🇪🇸
Hospital Universitario San Cecilio, Granada, Comunidad De Andalucia, Spain
🇪🇸
Hospital Universitario Infanta Leonor, Madrid, Spain

and more 10 locations

Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension

Phase 1

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Sulfasalazine's placebo
Drug: Sulfasalazine
Drug: Ambrisentan
Drug: Ambrisentan's placebo

First Posted Date: 2020-08-27

Last Posted Date: 2020-08-27

Lead Sponsor: RenJi Hospital

Target Recruit Count: 80

Registration Number: NCT04528056

Locations: 🇨🇳
Renji Hospital, Shanghai, China

mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms

Phase 2

Completed

Conditions: COVID-19

Interventions: Other: Standard of care
Drug: EDP1815
Drug: Dapagliflozin
Drug: Ambrisentan

First Posted Date: 2020-05-19

Last Posted Date: 2023-07-28

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 454

Registration Number: NCT04393246

Locations: 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom

A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis

Phase 2

Terminated

Conditions: Cirrhosis
Ascites
Portal Hypertension

Interventions: Drug: Ambrisentan

First Posted Date: 2019-02-01

Last Posted Date: 2021-02-26

Lead Sponsor: Noorik Biopharmaceuticals AG

Target Recruit Count: 19

Registration Number: NCT03827200

Locations: 🇪🇸
Hospital Clinic Barcelona, Barcelona, Catalunya, Spain
🇪🇸
Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain
🇪🇸
Vall d'Hebron University Hospital, Barcelona, Spain

and more 3 locations

Crossover Study From Macitentan or Bosentan Over to Ambrisentan

Phase 4

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Ambrisentan

First Posted Date: 2016-08-31

Last Posted Date: 2019-04-08

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 3

Registration Number: NCT02885012

Locations: 🇺🇸
Ochsner Medical Center, New Orleans, Louisiana, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

The Role of Endothelin-1 in Sickle Cell Disease

Phase 1

Completed

Conditions: Sickle Cell Anemia

Interventions: Drug: Placebo
Drug: Ambrisentan

First Posted Date: 2016-03-18

Last Posted Date: 2020-04-02

Lead Sponsor: Augusta University

Target Recruit Count: 26

Registration Number: NCT02712346

Locations: 🇺🇸
Augusta University, Augusta, Georgia, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy